Under accelerated review status, the FDA approves Blueprint Medicine’s (NASDAQ:BPMC) Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
The company will co-commercialize the once-daily RET inhibitor in the U.S. with Roche’s Genentech. Market launch will commence within one week.
Roche will commercialize ex-U.S. excluding Greater China.
Management will host a webcast this morning at 8:00 am ET to discuss the nod.
https://seekingalpha.com/news/3611972-fda-oks-blueprints-pralsetinib-for-certain-type-of-lung-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.